A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Withdrawn before enrolling · Phase 1 · Has a placebo group

Conditions studied: Myocardial Infarction, Myocardial Ischemia

In brief

The purpose of this study is to determine whether the intravenous administration of single- and multiple-ascending doses of Thymosin Beta 4 is safe and tolerable in healthy volunteers.

Key facts

Study ID

NCT00743769

Run by

RegeneRx Biopharmaceuticals, Inc.

People needed

0

Starts

2008-04-01

Expected to finish

2017-01-01

Last updated by the study team

2017-04-17

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• In good health with no underlying medical condition that, according to the Investigator, would place a subject at risk
• Having given written informed consent

You may not qualify if…

• Evidence of any malignancy
• Use of any tobacco product within 7 years of study entry
• Pregnant or lactating women
• History of drug abuse
• Clinically significant abnormal screening ECG
• Abnormal vital signs
• Use of systemic steroidal therapy), immunotherapy, cytotoxic, chemotherapy or any investigational drug or device within 30 days of study entry. Topical steroids are allowed
• Women, 40 years of age and above, who have not had a mammography within one year of study entry
• Men and women, 50 years of age and above, who have not had a sigmoidoscopy within 5 years and colonoscopy within 10 years of study entry

Where it is running

• Healthcare Discoveries LLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.